^
BIOMARKER:

EGFR exon 19 mutation

i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR exon 19 mutation
NSCLC
erlotinib
Sensitive: A2 - Guideline
EGFR exon 19 mutation
NSCLC
erlotinib + ramucirumab
Sensitive: B - Late Trials
EGFR exon 19 mutation
NSCLC
icotinib
Sensitive: B - Late Trials
EGFR exon 19 mutation
LUAD
bevacizumab + erlotinib
Sensitive: C3 – Early Trials
EGFR exon 19 mutation
NSCLC
gefitinib
Sensitive: C3 – Early Trials
EGFR exon 19 mutation
LUAD
erlotinib
Sensitive: C3 – Early Trials
EGFR exon 19 mutation
NSCLC
cisplatin + gefitinib + docetaxel
Sensitive: C3 – Early Trials
EGFR exon 19 mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
EGFR exon 19 mutation
Pancreatic Adenocarcinoma
erlotinib
Sensitive: C4 – Case Studies
EGFR exon 19 mutation
Small Cell Lung Cancer
osimertinib
Sensitive: C4 – Case Studies